Filing Flows › Health Care › Nuo Therapeutics (AURX)
Nuo Therapeutics (AURX) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · Nuo Therapeutics (AURX) Q2 2026 earnings results →
Q2 2026 Revenue up 153% year over year to $1.8M · 16¢ of every $1 of revenue lost · operating margin -9.4%
Nuo Therapeutics made $1.8M in Q2 2026 (+153% Y/Y): Product $1.7M, Aurix and Private Label Centrifuge Devices $72K. Operating margin -9.4%, net loss $278K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.8M in Q2 2026, up 153% year over year and up 36% from the previous quarter. Aurix and Private Label Kits was the largest line at 92% of revenue. License added $3K year over year (up 4%), 0% of the total change.
Gross margin was 66.1%, down 11.1 points from Q2 2025. Operating costs exceeded revenue by $167K, an operating margin of -9.4%. Operating expenses grew 12% against revenue growth of 153%. The quarter ended with a net loss of $278K, narrower than the previous quarter's $618K loss.
Operating cash flow was −$236K. Non-cash charges added back $26K of depreciation and $41K of share-based compensation. Working capital and other items used $27K. Capital expenditures of $253K exceeded it, leaving free cash flow of −$490K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $1.8M | +153% | -9.4% | −$278K | −$236K |
| Q1 2026 | 10-Q | May 14, 2026 | $1.3M | +169% | -34.3% | −$618K | −$784K |
| Q4 2025 | 10-K | Mar 30, 2026 | $1.1M | +178% | -52.8% | −$578K | −$423K |
| Q3 2025 | 10-Q | Oct 30, 2025 | $1.0M | +178% | -52.3% | −$538K | −$707K |
| Q2 2025 | 10-Q | Jul 31, 2025 | $700K | +92% | -93.1% | −$650K | $262K |
| Q1 2025 | 10-Q | Apr 30, 2025 | $484K | +106% | -153.8% | −$746K | $2K |
| Q4 2024 | 10-K | Apr 1, 2025 | $395K | +100% | -159.4% | −$497K | −$491K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Nuo Therapeutics
Nuo Therapeutics, Inc. is a Delaware corporation organized in 1998 under the name Informatix Holdings, Inc. In 1999, Autologous Wound Therapy, Inc., an Arkansas Corporation, merged with and into Informatix Holdings, Inc. and the name of the surviving corporation was changed to Autologous Wound Therapy, Inc. In 2000, Autologous Wound Therapy, Inc. changed its name to Cytomedix, Inc. (“Cytomedix”). In 2001, Cytomedix, filed for bankruptcy, from which it emerged in 2002 under a Plan of Reorganization. In September 2007, Cytomedix received Section 510(k) clearance from the U. S. Food and Drug Administration (“FDA”) for the AutoloGel™ System, now known as the Aurix System (“Aurix”), for processing peripheral blood into an autologous platelet rich plasma ("PRP") for wound management .
In its own words, from its 10-K, filed Mar 30, 2026.
Nuo Therapeutics against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +153% against the peers' median +5%. Operating margin: -9.4% against the peers' median 13.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| AURX Nuo Therapeutics | Q2 2026 | $1.8M | +153% | -9.4% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: Nuo Therapeutics 10-Q on SEC EDGAR · CIK 1091596 · Surgical & Medical Instruments & Apparatus
13F: who owns AURX and who is buying
More on AURX
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results